Key statistics
On Wednesday, Recordati Industria Chimica e Farmaceutica SpA (RECN:MEX) closed at 1,188.76, 0.00% below its 52-week high of 1,188.76, set on Feb 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 1,188.76 |
| Low | 1,188.76 |
| Bid | -- |
| Offer | -- |
| Previous close | 1,188.76 |
| Average volume | -- |
|---|---|
| Shares outstanding | 209.13m |
| Free float | 111.21m |
| P/E (TTM) | 24.45 |
| Market cap | 10.04bn EUR |
| EPS (TTM) | 1.96 EUR |
| Annual div (ADY) | 27.66 MXN |
|---|---|
| Annual div yield (ADY) | -- |
| Div ex-date | Nov 25 2025 |
| Div pay-date | Nov 26 2025 |
Data delayed at least 20 minutes, as of Feb 19 2025 11:30 GMT.
More ▼
Announcements
- RECORDATI ANNUNCIA UNA COLLABORAZIONE STRATEGICA CON MODERNA PER SVILUPPARE E COMMERCIALIZZARE A LIVELLO GLOBALE mRNA-3927 PER IL TRATTAMENTO DELL’ACIDEMIA PROPIONICA
- RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
- RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
- RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
- Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology
- RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
- RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
- RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
- RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
- RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
More ▼
